[ SYSAIQ—NEWS / INDUSTRY ]
Enveda secures $311M to bring more nature-derived AI drugs into clinical trials
Enveda, a biotech startup, has raised $311 million in a Series E funding round. The company is currently testing drugs aimed at treating skin conditions and maintaining weight loss.
Why it matters
This funding could lead to significant advancements in the pharmaceutical industry and new treatment options.
Source: TechCrunch — AI — Read the original story
This brief was prepared with AI assistance from the source text and reviewed before publication; see the original source for full details.
Want this capability in your business?
Tell us about your business and what you want to automate or make smarter; you receive a written proposal before any commitment.
See our services Start a project